N-[5-(2-Chloroethyl)-8-hydroxy-3-methyl-6-quinolinyl]-5,6,7-trimethoxy-1H-indole-2-carboxamide | 1242167-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[5-(2-Chloroethyl)-8-hydroxy-3-methyl-6-quinolinyl]-5,6,7-trimethoxy-1H-indole-2-carboxamide
• 英文别名: N-[5-(2-chloroethyl)-8-hydroxy-3-methylquinolin-6-yl]-5,6,7-trimethoxy-1H-indole-2-carboxamide
• CAS: 1242167-44-7
• 化学式: C₂₄H₂₄ClN₃O₅
• 分子量: 469.925
• InChiKey: VKXNGXPENZNMFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  106
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 palladium 10% on activated carbon 、 甲酸铵 作用下， 以 四氢呋喃 、 水 为溶剂， 以50%的产率得到N-[5-(2-Chloroethyl)-8-hydroxy-3-methyl-6-quinolinyl]-5,6,7-trimethoxy-1H-indole-2-carboxamide
  参考文献：
  名称：

  A novel achiral seco-cyclopropylpyrido[e]indolone (CPyI) analog of CC-1065 and the duocarmycins: Synthesis, DNA interactions, in vivo anticancer and anti-parasitic evaluation

  摘要：

  The synthesis of an achiral seco-hydroxy-aza-CBI-TMI analog (8) of the duocarmycins is reported. Its specificity for the DNA minor groove of AT-rich sequences and covalent bonding to adenine-N3 was ascertained by a thermal cleavage assay. Compound 8 was found to be cytotoxic in the nanomolar range against murine and human cancer cells. It was further demonstrated that compound 8 was active against murine melanoma (B16-F0) grown in C57BL/6 mice. Compound 8 was also shown to inhibit the growth of the protozoan parasites Leishmania donovani, Leishmania mexicana, Trypanosoma brucei, and Plasmodium falciparum in culture. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.05.078

文献信息

• BLOOD STAGE MALARIA VACCINE
  申请人：Griffith University

  公开号：EP2714075B1

  公开（公告）日：2016-11-16
• Blood Stage Malaria Vaccine
  申请人：Good Michael

  公开号：US20140186402A1

  公开（公告）日：2014-07-03

  An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of Plasmodium used in the immunogenic composition, or by one or more heterologous isolates, strains or species of Plasmodium.
• COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS
  申请人：Merck Patent GmbH

  公开号：US20210369705A1

  公开（公告）日：2021-12-02

  The present invention relates to synergistic combinations of DNA-alkylating ADCs and ATR inhibitors.
• US9539316B2
  申请人：——

  公开号：US9539316B2

  公开（公告）日：2017-01-10
• [EN] BLOOD STAGE MALARIA VACCINE<br/>[FR] VACCIN CONTRE LE PALUDISME AU STADE SANGUIN
  申请人：UNIV GRIFFITH

  公开号：WO2012162731A1

  公开（公告）日：2012-12-06

  An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of Plasmodium used in the immunogenic composition, or by one or more heterologous isolates, strains or species of Plasmodium.